PL362692A1 - Agoniści receptora alfa aktywowanego proliferatorem peroksyzomu - Google Patents

Agoniści receptora alfa aktywowanego proliferatorem peroksyzomu

Info

Publication number
PL362692A1
PL362692A1 PL01362692A PL36269201A PL362692A1 PL 362692 A1 PL362692 A1 PL 362692A1 PL 01362692 A PL01362692 A PL 01362692A PL 36269201 A PL36269201 A PL 36269201A PL 362692 A1 PL362692 A1 PL 362692A1
Authority
PL
Poland
Prior art keywords
activated receptor
receptor alpha
peroxisome proliferator
triazole derivatives
proliferator activated
Prior art date
Application number
PL01362692A
Other languages
English (en)
Inventor
Cano Ivan Collado
Samuel James Dominianni
Garret Jay Etgen Jr.
Cristina Garcia-Paredes
Richard Duane Johnston
Michael Edward Letourneau
Nathan Bryan Mantlo
Michael John Martinelli
Daniel Ray Mayhugh
Ashraf Saeed
Richard Craig Thompson
Xiadong Wang
David Scott Coffey
Christopher Randall Schmid
Jeffrey Thomas Vicenzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL362692A1 publication Critical patent/PL362692A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/22—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C07C281/04—Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cultivation Of Plants (AREA)
PL01362692A 2000-11-10 2001-11-09 Agoniści receptora alfa aktywowanego proliferatorem peroksyzomu PL362692A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24731700P 2000-11-10 2000-11-10
PCT/US2001/042928 WO2002038553A2 (en) 2000-11-10 2001-11-09 Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists

Publications (1)

Publication Number Publication Date
PL362692A1 true PL362692A1 (pl) 2004-11-02

Family

ID=22934453

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01362692A PL362692A1 (pl) 2000-11-10 2001-11-09 Agoniści receptora alfa aktywowanego proliferatorem peroksyzomu

Country Status (34)

Country Link
US (3) US7304062B2 (pl)
EP (1) EP1335908B1 (pl)
JP (1) JP4243101B2 (pl)
KR (1) KR100839705B1 (pl)
CN (1) CN1479728A (pl)
AR (1) AR031305A1 (pl)
AT (1) ATE386026T1 (pl)
AU (3) AU2002228592B8 (pl)
BR (1) BR0114986A (pl)
CA (1) CA2421154A1 (pl)
CY (1) CY1107388T1 (pl)
CZ (1) CZ20031283A3 (pl)
DE (1) DE60132799T2 (pl)
DK (1) DK1335908T3 (pl)
EA (1) EA006920B1 (pl)
EC (1) ECSP034595A (pl)
ES (1) ES2300378T3 (pl)
HR (1) HRP20030365A2 (pl)
HU (1) HUP0301655A2 (pl)
IL (2) IL154840A0 (pl)
MX (1) MXPA03004141A (pl)
MY (1) MY157884A (pl)
NO (1) NO20032059L (pl)
NZ (1) NZ524569A (pl)
PE (1) PE20020693A1 (pl)
PL (1) PL362692A1 (pl)
PT (1) PT1335908E (pl)
SI (1) SI1335908T1 (pl)
SK (1) SK5412003A3 (pl)
SV (1) SV2003000727A (pl)
TW (1) TW200716572A (pl)
UA (1) UA82048C2 (pl)
WO (1) WO2002038553A2 (pl)
ZA (1) ZA200302517B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205321B2 (en) 2001-11-15 2007-04-17 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1517882A1 (en) 2002-06-19 2005-03-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
KR100803481B1 (ko) * 2004-07-27 2008-02-14 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물
WO2006010545A1 (en) * 2004-07-27 2006-02-02 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
MX2007001634A (es) * 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
WO2006068199A1 (ja) * 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
PE20061041A1 (es) * 2005-01-28 2006-10-12 Lilly Co Eli Formulaciones y regimen de dosificacion para moduladores alfa de ppar
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
CN101189231B (zh) * 2005-03-23 2011-05-18 杏林制药株式会社 环状氨基苯基链烷酸衍生物
CN101180280A (zh) * 2005-03-24 2008-05-14 弗·哈夫曼-拉罗切有限公司 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
CA2678846A1 (en) * 2007-02-23 2008-08-28 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
BRPI0809617A2 (pt) 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
WO2010002712A2 (en) * 2008-06-30 2010-01-07 3M Innovative Properties Company Method of crystallization
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
CA2744985C (en) 2008-12-01 2014-05-06 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring useful for the prevention or treatment of hyperlipidemia
US8575430B2 (en) * 2010-03-02 2013-11-05 Nunhems, B.V. Hybrid artichoke variety NUN 4006 AR
US20110167512A1 (en) * 2009-03-02 2011-07-07 Nunhems B.V. Hybrid artichoke variety nun 4006 ar
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US20100245582A1 (en) * 2009-03-25 2010-09-30 Syclipse Technologies, Inc. System and method of remote surveillance and applications therefor
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8648233B2 (en) * 2010-09-20 2014-02-11 Nunhems B.V. Hybrid artichoke variety NUN 4021 AR
US8669420B2 (en) 2012-02-29 2014-03-11 Nunhems B.V. Hybrid artichoke variety NUN 4060 AR
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US9776976B2 (en) * 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
RU177130U1 (ru) * 2017-11-29 2018-02-09 Владимир Алексеевич Коннов Плита изоляционная облицовочная
JPWO2021205803A1 (pl) 2020-04-10 2021-10-14
CN112774869B (zh) * 2020-12-25 2022-09-16 厦门紫金矿冶技术有限公司 黄铁矿抑制剂及其制备和在铜铅锌多金属硫化矿中的应用
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379B (zh) * 2022-01-20 2025-06-27 哈尔滨三联药业股份有限公司 海因类化合物及其医药用途
CN114563394B (zh) * 2022-02-10 2025-03-11 湖南东方钪业股份有限公司 一种氟化钪中杂质含量的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
DE19517505A1 (de) * 1995-05-12 1996-11-14 Bayer Ag Sulfonylamino(thio)carbonyltriazolin(thi)one mit Aryloxy- oder Arylthio-Substituenten
EP0858457A1 (de) * 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
AU9462198A (en) * 1997-10-17 1999-05-10 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
ATE286032T1 (de) * 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
USPP14578P2 (en) * 2002-09-23 2004-03-09 Plant Sciences, Inc. Artichoke plant named ‘PS-MSC0003’

Also Published As

Publication number Publication date
US20090044299A1 (en) 2009-02-12
DK1335908T3 (da) 2008-06-02
CA2421154A1 (en) 2002-05-16
MXPA03004141A (es) 2003-08-19
SI1335908T1 (sl) 2008-08-31
MY157884A (en) 2016-08-01
DE60132799D1 (de) 2008-03-27
AU2002228592B2 (en) 2006-04-27
CN1479728A (zh) 2004-03-03
IL154840A (en) 2009-09-22
US7868225B2 (en) 2011-01-11
US20090062358A1 (en) 2009-03-05
NO20032059L (no) 2003-06-24
ZA200302517B (en) 2004-06-30
WO2002038553A2 (en) 2002-05-16
KR100839705B1 (ko) 2008-06-19
US7304062B2 (en) 2007-12-04
AU2002228592B8 (en) 2006-08-24
SV2003000727A (es) 2003-01-13
JP4243101B2 (ja) 2009-03-25
CZ20031283A3 (cs) 2003-09-17
EA200300558A1 (ru) 2004-02-26
JP2004513166A (ja) 2004-04-30
NZ524569A (en) 2006-05-26
ECSP034595A (es) 2003-06-25
WO2002038553A3 (en) 2003-05-01
IL154840A0 (en) 2003-10-31
BR0114986A (pt) 2003-09-23
DE60132799T2 (de) 2009-03-19
HRP20030365A2 (en) 2003-08-31
KR20030048133A (ko) 2003-06-18
US20040102500A1 (en) 2004-05-27
HK1058790A1 (en) 2004-06-04
ES2300378T3 (es) 2008-06-16
EA006920B1 (ru) 2006-04-28
EP1335908B1 (en) 2008-02-13
SK5412003A3 (en) 2004-01-08
UA82048C2 (uk) 2008-03-11
HUP0301655A2 (hu) 2003-12-29
AU2859202A (en) 2002-05-21
PT1335908E (pt) 2008-05-08
ATE386026T1 (de) 2008-03-15
AU2006202811A1 (en) 2006-07-20
EP1335908A2 (en) 2003-08-20
TW200716572A (en) 2007-05-01
AR031305A1 (es) 2003-09-17
NO20032059D0 (no) 2003-05-08
CY1107388T1 (el) 2012-12-19
PE20020693A1 (es) 2002-08-05

Similar Documents

Publication Publication Date Title
PL362692A1 (pl) Agoniści receptora alfa aktywowanego proliferatorem peroksyzomu
IL155634A0 (en) 3-arylindole derivatives and their use as cb2 receptor agonists
PT1526132E (pt) Derivados de oxazolidinona substituídos e sua utilização enquanto inibidores do factor xa
IL156487A0 (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
HUP0304051A3 (en) Furan and thiophene derivatives activating the human peroxisome proliferator activated receptors
HUP0203532A3 (en) Substituted oxazoles and thiazoles derivatives as hppar alpha activators, pharmaceutical compositions containing them and their use
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
IL161578A0 (en) Peroxisome proliferator activated receptor agonists
SI1170288T1 (en) Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists
AU2002224138A1 (en) Peroxisome proliferator activated receptor d activators
AU2002224139A1 (en) Ppar (peroxisome proliferator activated receptor) activators
EP1284735A4 (en) APOMORPHINE DERIVATIVES AND METHODS OF USE
IL155937A0 (en) Imidazole and benzimidazole derivatives and pharmaceutical compositions containing the same
IL146110A0 (en) Thiazolidinedione derivative and its use as antidiabetic
HUP0203121A3 (en) Pharmaceutical composition containing substituted benzimidazoles and its use
PT1464641E (pt) Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetrahidropiridilo como antagonistas da dopamina d4
AU2002347985A1 (en) Peroxisome proliferator activated receptor alpha agonists
AUPQ570100A0 (en) Beta-alanine derivatives and their use as receptor antagonists
HRP20010770B1 (en) Thiazolidinedione derivative and its use as antidiabetic
HRP20010771B1 (en) Thiazolidinedione derivative and its use as antidiabetic
AU2001289735A1 (en) Chromenone derivatives and their use for treating diseases in conjunction with 5-HTA 1 receptors and/or dopamine D2 receptors
HK1071563A (en) Peroxisome proliferator activated receptor agonists
AU2000229045A1 (en) Benzimidazole derivatives and their use as factor xa inhibitors
HK1055961A (en) 3-arylindole derivatives and their use as cb2 receptor agonists
SI1173434T1 (en) Thiazolidinedione derivative and its use as antidiabetic

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)